

SINGAPORE MEDICAL GROUP LIMITED

(Incorporated in the Republic of Singapore)

(UEN/Company Registration No. 200503187W)

ANNOUNCEMENT

RESULTS OF THE INVITATION TO NOTEHOLDERS TO OFFER TO SELL FOR CASH S\$90,000,000 3.54 PER CENT. NOTES DUE 2029 (ISIN: SGXF13889278) GUARANTEED BY CREDIT GUARANTEE AND INVESTMENT FACILITY, A TRUST FUND OF THE ASIAN DEVELOPMENT BANK

The Singapore Exchange Securities Trading Limited ("SGX-ST") takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.

1. INTRODUCTION

Singapore Medical Group Limited (the "**Issuer**") refers to:

- (a) its announcement dated 13 August 2026 (the "**Invitation Announcement**") in relation to the invitation (the "**Invitation**") to holders ("**Noteholders**") of its outstanding S\$90,000,000 3.54 per cent. Notes due 2029 (ISIN: SGXF13889278) (the "**Notes**") guaranteed by Credit Guarantee and Investment Facility, a trust fund of the Asian Development Bank (the "**Guarantor**"), to offer to sell for cash to the Issuer up to S\$31,500,000 in aggregate principal amount of the outstanding Notes held by Noteholders (the "**Maximum Acceptance Amount**"), subject to the terms and conditions set out in the invitation memorandum dated 13 August 2026 (the "**Invitation Memorandum**"); and
- (b) its announcement dated 21 August 2026 in relation to the extension of the Expiration Deadline to 5:30 p.m. (Singapore time) on 26 August 2026 and the Settlement Date to 31 August 2026.

Capitalised terms used but not defined herein shall have the meanings given to them in the Invitation Memorandum.

2. RESULTS OF THE INVITATION

The Expiration Deadline for the Invitation was 5:30 p.m. (Singapore time) on 26 August 2026.

As at the Expiration Deadline, Tender Application Forms were received in respect of an aggregate principal amount of **S\$64,000,000** of Notes offered for sale pursuant to the Invitation.

As the aggregate principal amount of Notes offered for sale (S\$64,000,000) exceeds the Maximum Acceptance Amount (S\$31,500,000), Tender Application Forms have been accepted on a pro rata basis in accordance with the terms of the Invitation Memorandum. The Issuer hereby announces that it will accept for purchase an aggregate principal amount of **S\$31,500,000** of Notes (the "**Final Accepted Notes**"), being equal to the Maximum Acceptance Amount.

3. PRO-RATION

In accordance with the terms of the Invitation Memorandum, Tender Application Forms have been scaled on a pro rata basis by a scaling factor of approximately **0.492188** (the "**Scaling Factor**"), being the Maximum Acceptance Amount (S\$31,500,000) divided by the aggregate principal amount of Notes validly offered for sale (S\$64,000,000), subject to rounding to the nearest S\$1,000 in principal amount and such adjustments as the Issuer has determined in its sole discretion in accordance with the Invitation Memorandum.

Noteholders whose Tender Application Forms have been scaled will have the balance of their Notes (being the portion not accepted for purchase) released from earmarking by CDP following settlement of the Invitation.

4. SETTLEMENT

The Settlement Date for the Final Accepted Notes is expected to be 31 August 2026. Each Noteholder whose Notes have been accepted for purchase by the Issuer will receive, on the Settlement Date:

- (a) the Purchase Price of 104.850 per cent. of the principal amount of the Final Accepted Notes (being S\$262,125 for each S\$250,000 in principal amount of Notes); and
- (b) the Accrued Interest on the Final Accepted Notes from (and including) 20 May 2026 up to (but excluding) the Settlement Date.

Payment will be made to the bank account specified by the relevant Noteholder in its Tender Application Form.

5. NOTES REMAINING OUTSTANDING

Following settlement of the Invitation, the aggregate principal amount of the Notes that will remain outstanding will be **S\$58,500,000**.

6. DEALER MANAGERS AND TENDER AGENT

Questions or requests for information in relation to the Invitation should be directed to:

Dealer Managers:

DBS Bank Ltd.

12 Marina Boulevard, Level 42 Marina Bay Financial Centre Tower 3, Singapore 018982

Tel: +65 6222 4261

Email: liabilitymanagement@dbs.com

Oversea-Chinese Banking Corporation Limited

63 Chulia Street, #03-01 OCBC Centre East, Singapore 049514

Email: liabilitymanagement@ocbc.com

Tender Agent:

Tricor Barbinder Share Registration Services (a division of Tricor Singapore Pte. Ltd.)

9 Raffles Place, #26-01 Republic Plaza, Singapore 048619

Telephone: +65 6236 3555

Email: is.corporateactions@vistra.com

7. IMPORTANT NOTICE

None of the Issuer, the Guarantor, the Dealer Managers, the Trustee or the Tender Agent makes any recommendation as to the merits of the Invitation. The Invitation is not being made, directly or indirectly, in or into the United States.

By Order of the Board

SINGAPORE MEDICAL GROUP LIMITED

Dr Beng Teck Liang
Executive Director and Chief Executive Officer

28 August 2026